Patents by Inventor Xingyue Ji
Xingyue Ji has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11685711Abstract: The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs.Type: GrantFiled: August 9, 2018Date of Patent: June 27, 2023Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Ladie Kimberly c. De La Cruz, Xingyue Ji, Zhixiang Pan, Binghe Wang
-
Patent number: 11607458Abstract: Disclosed herein is a chemical delivery system having: i) a cargo compound comprising a first reactive moiety covalently bonded to a first enrichment moiety and a tethered cargo moiety, wherein the first reactive moiety is bonded to the tethered cargo moiety via a cleavable linker; and ii) a trigger compound comprising a second reactive moiety covalently bonded to a second enrichment moiety and a cargo-releasing moiety. The first enrichment moiety and the second enrichment moiety cause an increase in concentration of the cargo compound and the concentration of the trigger compound at a target site, causing a bimolecular reaction between the first reactive moiety and the second reactive moiety to form a cyclization precursor compound. The cargo moiety is then released from the cyclization precursor compound in a unimolecular cyclization reaction. Methods for treating conditions such as cancer, inflammatory conditions, and infections with the chemical delivery systems are also described.Type: GrantFiled: October 25, 2018Date of Patent: March 21, 2023Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Binghe Wang, Yueqin Zheng, Xingyue Ji, Robert Emuobonuvie Aghoghovbia
-
Patent number: 11420994Abstract: Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37° C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.Type: GrantFiled: November 15, 2017Date of Patent: August 23, 2022Assignee: Georgia State University Research Foundation, Inc.Inventors: Binghe Wang, Xingyue Ji, Zhixiang Pan
-
Patent number: 11377435Abstract: The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs. The compounds disclosed herein contain a cyclopentadienone moiety, a non-reactive dienophile, and an enzyme-cleavable tethering moiety connecting the cyclopentadienone moiety to the non-reactive dienophile. Cleavage of the enzyme-cleavable tethering moiety results in conversion of the non-reactive dienophile to a reactive dienophile.Type: GrantFiled: December 12, 2019Date of Patent: July 5, 2022Assignee: Georgia State University Research Foundation, Inc.Inventors: Binghe Wang, Xingyue Ji
-
Publication number: 20210238155Abstract: The present invention provides new compounds and compositions thereof that release carbon monoxide for the treatment of medical disorders that are responsive to carbon monoxide, for example, inflammatory, pain, and dermatological disorders.Type: ApplicationFiled: April 16, 2021Publication date: August 5, 2021Applicant: Georgia State University Research Foundation, Inc.Inventors: Binghe Wang, Xingyue Ji, Ladie Kim De La Cruz, Xiaoxiao Yang
-
Publication number: 20210000965Abstract: Disclosed herein is a chemical delivery system having: i) a cargo compound comprising a first reactive moiety covalently bonded to a first enrichment moiety and a tethered cargo moiety, wherein the first reactive moiety is bonded to the tethered cargo moiety via a cleavable linker; and ii) a trigger compound comprising a second reactive moiety covalently bonded to a second enrichment moiety and a cargo-releasing moiety. The first enrichment moiety and the second enrichment moiety cause an increase in concentration of the cargo compound and the concentration of the trigger compound at a target site, causing a bimolecular reaction between the first reactive moiety and the second reactive moiety to form a cyclization precursor compound. The cargo moiety is then released from the cyclization precursor compound in a unimolecular cyclization reaction. Methods for treating conditions such as cancer, inflammatory conditions, and infections with the chemical delivery systems are also described.Type: ApplicationFiled: October 25, 2018Publication date: January 7, 2021Applicant: Georgia State University Research Foundation, IncInventors: Binghe Wang, Yueqin Zheng, Xingyue Ji, Robert Emuobonuvie Aghoghovbia
-
Patent number: 10772858Abstract: This disclosure relates to benzhydrol derivatives for managing conditions related to the Hypoxia Inducible Factor (HIF) pathway such as uses in treating cancer. In certain embodiment, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiment, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof.Type: GrantFiled: May 2, 2016Date of Patent: September 15, 2020Assignees: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC., EMORY UNIVERSITYInventors: Binghe Wang, Erwin Van Meir, Jalisa Holmes Ferguson, Stefan Kaluz, Xingyue Ji
-
Publication number: 20200283382Abstract: The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs.Type: ApplicationFiled: August 9, 2018Publication date: September 10, 2020Applicant: Georgia State University Research Foundation, Inc.Inventors: Ladie Kimberly c. De La Cruz, Xingyue Ji, Zhixiang Pan, Binghe Wang
-
Patent number: 10751344Abstract: Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37° C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.Type: GrantFiled: May 27, 2019Date of Patent: August 25, 2020Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC.Inventors: Binghe Wang, Danzhu Wang, Xingyue Ji, Alexander Draganov, Chaofeng Dai, Krishna Damera, Didier Merlin, Emilie Viennois, Yueqin Zheng
-
Publication number: 20200115360Abstract: The present invention generally relates to carbon monoxide releasing compounds and compositions, and their use as carbon monoxide prodrugs. The compounds disclosed herein contain a cyclopentadienone moiety, a non-reactive dienophile, and an enzyme-cleavable tethering moiety connecting the cyclopentadienone moiety to the non-reactive dienophile.Type: ApplicationFiled: December 12, 2019Publication date: April 16, 2020Inventors: Binghe Wang, Xingyue Ji
-
Publication number: 20190350937Abstract: Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37° C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.Type: ApplicationFiled: May 27, 2019Publication date: November 21, 2019Inventors: Binghe Wang, Danzhu Wang, Xingyue Ji, Alexander Draganov, Chaofeng Dai, Krishna Damera, Didier Merlin, Emilie Viennois, Yueqin Zheng
-
Patent number: 10300069Abstract: Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37 C and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.Type: GrantFiled: June 9, 2015Date of Patent: May 28, 2019Assignee: Georgia State University Research Foundation, Inc.Inventors: Binghe Wang, Danzhu Wang, Xingyue Ji, Alexander Draganov, Chaofeng Dai, Krishna Damera, Didier Merlin, Emilie Viennois, Yueqin Zheng
-
Publication number: 20180289664Abstract: This disclosure relates to benzhydrol derivatives for managing conditions related to the Hypoxia Inducible Factor (HIF) pathway such as uses in treating cancer. In certain embodiment, the disclosure contemplates compounds and pharmaceutical compositions. In certain embodiment, the disclosure contemplates compounds disclosed herein as prodrugs, optionally substituted with one or more substituents, derivatives, or salts thereof.Type: ApplicationFiled: May 2, 2016Publication date: October 11, 2018Inventors: Binghe Wang, Erwin Van Meir, Jalisa Nicole Holmes, Stefan Kaluz, Xingyue Ji
-
Publication number: 20170128456Abstract: Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37 C and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.Type: ApplicationFiled: June 9, 2015Publication date: May 11, 2017Applicant: Georgia State University Research Foundation, Inc,Inventors: Binghe Wang, Danzhu Wang, Xingyue Ji, Alexander Draganov, Chaofeng Dai, Krishna Damera, Didier Merlin, Emilie Viennois, Yueqin Zheng
-
Patent number: 9359298Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.Type: GrantFiled: December 18, 2012Date of Patent: June 7, 2016Assignee: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Zhuorong Li, Xingyue Ji, Situ Xue, Guanghui Zheng, Yuhuan Li, Peizhen Tao, Jiandong Jiang
-
Publication number: 20140371232Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.Type: ApplicationFiled: December 18, 2012Publication date: December 18, 2014Inventors: Zhuorong Li, Xingyue Ji, Situ Xue, Guanghui Zheng, Yuhuan Li, Peizhen Tao, Jiandong Jiang